Undersea and Hyperbaric Medicine最新文献

Hyperbaric Oxygen Therapy Regimens, Treated Conditions, and Adverse Effect Profile: an Undersea and Hyperbaric Medical Society Survey Study. 高压氧治疗方案、治疗条件和不良反应概况：海底和高压氧医学学会调查研究。

IF 0.7 4区医学

Undersea and Hyperbaric Medicine Pub Date : 2024-04-01

Matteo Laspro, Lucy W Wei, Hilliard T Brydges, Scott A Gorenstein, Enoch T Huang, Ernest S Chiu

{"title":"Hyperbaric Oxygen Therapy Regimens, Treated Conditions, and Adverse Effect Profile: an Undersea and Hyperbaric Medical Society Survey Study.","authors":"Matteo Laspro, Lucy W Wei, Hilliard T Brydges, Scott A Gorenstein, Enoch T Huang, Ernest S Chiu","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: When administering HBO2 , pressures can range from 1.4 atmospheres absolute (ATA) to 3 ATA. While different treatment profiles have been proposed, there is a paucity of literature comparing the effectiveness and risk profile associated with different pressures treating the same condition. Considering the therapeutic divergence, this study aims to survey Undersea and Hyperbaric Medical Society (UHMS) members on pressure modalities and their use in different clinical conditions.Methods: The study was a voluntary cross-sectional survey administered online and open to healthcare providers who were Undersea and Hyperbaric Medical Society members. UHMS itself distributed the survey link. The survey period lasted from November 2022 until January 2023. Data were collected utilizing the Qualtrics platform and analyzed through Microsoft Excel.Results: A total of 265 responses were recorded. The majority responded with utilizing 2.4 ATA (35.2%) as the pressure of choice, followed by 2.0 ATA only (27.1%), and those who utilized differing therapeutic pressures (26.4%). The overwhelming choice for treatment of osteoradionecrosis (ORN) of the jaw, radiation proctitis/cystitis, diabetic foot ulcer, and chronic osteomyelitis was 2.0 ATA (68.0- 74.9%). Among listed adverse effects, myopia was the most commonly reported complication at 24.4%, followed by barotrauma (14.9%) and confinement anxiety (11.5%).Conclusions: There is currently little consensus regarding the best treatment modalities for conditions treated with HBO2. As adverse effects appear non-negligible, future prospective studies must be conducted weighing the risks and benefits of higher-pressure therapies compared to safer lower-pressure options.","PeriodicalId":49396,"journal":{"name":"Undersea and Hyperbaric Medicine","volume":"51 4","pages":"369-376"},"PeriodicalIF":0.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing the hyperbaric chamber pressurization profile during standard hyperbaric oxygen therapy. 在标准高压氧治疗期间优化高压氧室加压剖面。

IF 0.7 4区医学

Undersea and Hyperbaric Medicine Pub Date : 2024-04-01

Lyubisa Mátity, Francois Burman, Frans Cronje

引用次数: 0

Investigation Of The Effects Of Hyperbaric Oxygen Therapy On Hepatotoxicity Induced By Leflunomide in Rats. 高压氧治疗对来氟米特大鼠肝毒性影响的研究。

IF 0.7 4区医学

Undersea and Hyperbaric Medicine Pub Date : 2024-04-01

Ahmet Inal, Mohamad Hallak, Mehmet Akif Baktir, Görkem Ekebaş, Ayhan Atasever

{"title":"Investigation Of The Effects Of Hyperbaric Oxygen Therapy On Hepatotoxicity Induced By Leflunomide in Rats.","authors":"Ahmet Inal, Mohamad Hallak, Mehmet Akif Baktir, Görkem Ekebaş, Ayhan Atasever","doi":"","DOIUrl":"","url":null,"abstract":"Background: Hyperbaric Oxygen Therapy (HBO2) is a treatment modality that exposes patients to 100% oxygen at higher atmospheric pressures. Recently, HBO2 has emerged as a potential therapeutic option for various liver diseases, offering advantages such as improved tissue oxygenation, anti-inflammatory effects, enhanced wound healing, and potential hepatoprotective properties. Understanding the benefits of HBO2 in liver diseases can pave the way for novel therapeutic strategies and improved patient outcomes. This study aimed to investigate the hepatoprotective effect of HBO2 in arthritic rats treated with leflunomide (LEF) through anti-inflammatory and antioxidant pathways.Material and methods: 24 male Sprague-Dawley rats were divided into three groups (8 animals in each group (n = 8)). 1st group was the control group, which received no treatment. 2nd group was RA + LEF 5 mg/kg, 3rd group was RA + LEF 5 mg/kg + HBO2. Rheumatoid arthritis was induced using Complete Freund's Adjuvant (CFA). The treatment was initiated on the 10th day following induction and lasted for a total of 18 days. The impact on disease progression was assessed through histological changes, which were evaluated using hematoxylin-eosin staining, while the Anti-TNF-α antibody levels were determined.Results: TCompared with the RL group, the RLH group significantly decreases necrotic cells, Lymphocyte- rich mononuclear cells, and active anti-TNF-α .Conclusion: HBO2 showed a beneficial effect and decreased hepatotoxicity on Leflunomide-induced liver injury.","PeriodicalId":49396,"journal":{"name":"Undersea and Hyperbaric Medicine","volume":"51 4","pages":"353-359"},"PeriodicalIF":0.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Influence of hyperbaric air exposure on the function of brachial artery. 高压空气暴露对肱动脉功能的影响。

IF 0.7 4区医学

Undersea and Hyperbaric Medicine Pub Date : 2024-04-01

Zhang Ting-Ting, Guan Zhen-Biao, Xu Jia-Jun, Wang Shi-Feng, Liu Wen-Wu

引用次数: 0

REPRINTED FROM THE 2023 HYPERBARIC INDICATIONS MANUAL 15^th Edition: Sudden Sensorineural Hearing Loss. 转载自2023高压氧适应症手册第15版：突发性感音神经性听力损失。

IF 0.7 4区医学

Undersea and Hyperbaric Medicine Pub Date : 2024-04-01

Tracy Leigh LeGros, Heather Murphy-Lavoie

{"title":"REPRINTED FROM THE 2023 HYPERBARIC INDICATIONS MANUAL 15th Edition: Sudden Sensorineural Hearing Loss.","authors":"Tracy Leigh LeGros, Heather Murphy-Lavoie","doi":"","DOIUrl":"","url":null,"abstract":"Sudden sensorineural hearing loss (SSNHL) presents as the abrupt onset of hearing loss. Approximately 88% of SSNHL has no identifiable etiology and is termed idiopathic sudden sensorineural hearing loss (ISSHL). Hearing specialists have investigated ISSHL since the 1970s. Over the past 30 years, more than 800 articles, or one every two weeks, have been published in the English medical literature. ISSHL is the abrupt onset of hearing loss, usually unilaterally and upon wakening, that involves a hearing loss of at least 30 decibels (dB) occurring within three days over at least three contiguous frequencies. As most patients do not present with premorbid audiograms, the degree of hearing loss is usually defined by the presentation thresholds of the unaffected ear. Other associated symptoms include tinnitus, aural fullness, dizziness and vertigo. The historical incidence of ISSHL ranges from 5-20 cases/100,000 population, with approximately 4,000 new cases per annum in the United States. The true incidence is thought to be higher, as ISSHL is thought to be underreported. Interestingly, 4,000 cases annually calculate to 1.3 cases/ 100,000 in the United States; therefore, an incidence of 5-20/100,000 would translate to > 15,000 new ISSHL cases per annum in the United States. Recent literature has placed the annual ISSHL incidence in the United States as 27 cases/100,000, with a pediatric incidence of 11 cases/100,000. Other studies report that the incidence is increasing (160/100,000), especially in the elderly (77/100,000), and conclude that ISSHL is no longer rare. In 1984, Byl reviewed the literature and found the mean age of ISSHL presentation to be 46-49 years, with variation of incidence with age and an equal gender distribution. The presentation of ISSHL does not appear to have seasonal variations, uneven distributions of presentation throughout the year, or an association with upper respiratory infections, either prior to or following symptom onset. The spontaneous recovery is currently thought to be 30-60%.","PeriodicalId":49396,"journal":{"name":"Undersea and Hyperbaric Medicine","volume":"51 4","pages":"425-448"},"PeriodicalIF":0.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hyperbaric oxygen therapy for treatment of vascular occlusion after permanent dermal filler injection. 高压氧治疗永久性真皮填充物注射后血管闭塞。

IF 0.7 4区医学

Undersea and Hyperbaric Medicine Pub Date : 2024-04-01

Kelly Johnson-Arbor

{"title":"Hyperbaric oxygen therapy for treatment of vascular occlusion after permanent dermal filler injection.","authors":"Kelly Johnson-Arbor","doi":"","DOIUrl":"","url":null,"abstract":"Introduction: Arterial vascular occlusion is a rare complication of dermal filler injection. This case report describes the successful use of hyperbaric oxygen therapy in a patient with vascular occlusion after a permanent dermal filler was injected.Case report: A 51-year-old woman underwent an injection of non-resorbable polymethylmethacrylate microspheres into her nasolabial folds. Several hours later, she experienced dusky discoloration of the right nasolabial fold and surrounding livedo skin changes, consistent with vascular occlusion. Treatment with warm compresses and topical nitroglycerin was initiated, and the patient was referred for hyperbaric oxygen therapy. The tissue discoloration improved significantly after the administration of six hyperbaric treatments.Discussion: While hyaluronidase is recognized as a treatment option for vascular occlusion associated with using temporary fillers containing hyaluronic acid, it may also be beneficial for patients who experience vascular occlusion after administration of permanent fillers. Hyperbaric oxygen therapy, which results in hyperoxygenation of ischemic tissue and mitigation of the associated inflammatory response, may also benefit patients who experience vascular occlusion after permanent filler injection.Conclusions: Administration of hyaluronidase and hyperbaric oxygenation should be considered for patients who develop arterial occlusions after dermal filler placement, regardless of the type of injected filler.","PeriodicalId":49396,"journal":{"name":"Undersea and Hyperbaric Medicine","volume":"51 4","pages":"403-406"},"PeriodicalIF":0.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Does hyperbaric chamber attendance pose an asthma risk? Case report. 高压氧舱是否有哮喘风险？病例报告。

IF 0.7 4区医学

Undersea and Hyperbaric Medicine Pub Date : 2024-04-01

Levent Demir

引用次数: 0

Recovery from pulmonary oxygen toxicity: a new (ESOT) model. 肺氧中毒的恢复：一个新的（ESOT）模型。

IF 0.7 4区医学

Undersea and Hyperbaric Medicine Pub Date : 2024-04-01

Jan Risberg, Pieter-Jan van Ooij, Lyubisa Mátity

{"title":"Recovery from pulmonary oxygen toxicity: a new (ESOT) model.","authors":"Jan Risberg, Pieter-Jan van Ooij, Lyubisa Mátity","doi":"","DOIUrl":"","url":null,"abstract":"Arieli has previously demonstrated that the exposure metric K could be used to predict pulmonary oxygen toxicity (POT) based on changes in Vital Capacity (VC). Our previous findings indicate that the Equivalent Surface Oxygen Time (ESOT) allows the estimation of POT without loss of accuracy compared to K. In this work, we have further investigated POT recovery. The K metric assumes that the recovery of POT is to be controlled by exposure to pO2. This results in a counterintuitively slow estimated recovery after exposure to low pO2. Similarly, K overestimates POT during intermittent hyperoxic exposures. We used results from previous studies to train the parameters of a new ESOT recovery model. The predicted recovery of ESOT (ESOTrec) after initial hyperoxic exposure (ESOTI) of duration texp (h) and recovery time t (h) can be calculated as ESOTrec=ESOTI · e-f with f=0.439 · t · 0.906texp. For intermittent exposures, the function ESOT(n)=(n · a · ln(b · n+1)+c) · texp · pO22.285 will approximate POT (ESOT(n)) after n sessions of pO2 (atm) for time texp (min) in each cycle. Parameters a, b, and c are specific for each cycling pattern. These ESOT functions will better predict the development of POT during intermittent hyperoxic exposures as well as recovery after a broader range of continuous hyperoxic exposures than K. We recommend limiting hyperoxic exposures in surface-oriented diving to ESOT=660, 500, and 450 for a maximum of one, five, and seven consecutive days, respectively. A minimum of 48 hours of recovery should follow. These limits can probably be relaxed for intermittent exposures.","PeriodicalId":49396,"journal":{"name":"Undersea and Hyperbaric Medicine","volume":"51 4","pages":"407-423"},"PeriodicalIF":0.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hyperbaric Oxygen Therapy for Sudden Sensorineural Hearing Loss - A Comorbidity Lens. 高压氧治疗突发性感音神经性听力损失-一种合并症。

IF 0.7 4区医学

Undersea and Hyperbaric Medicine Pub Date : 2024-04-01

Aleeza J Leder Macek, Ronald S Wang, Justin Cottrell, Emily Kay-Rivest, Sean O McMenomey, J Thomas Roland, Frank L Ross

{"title":"Hyperbaric Oxygen Therapy for Sudden Sensorineural Hearing Loss - A Comorbidity Lens.","authors":"Aleeza J Leder Macek, Ronald S Wang, Justin Cottrell, Emily Kay-Rivest, Sean O McMenomey, J Thomas Roland, Frank L Ross","doi":"","DOIUrl":"","url":null,"abstract":"Objective: To determine the outcomes of patients receiving hyperbaric oxygen therapy for sudden sensorineural hearing loss and the impact of patient comorbidities on outcomes.Study design: Retrospective chart review.Setting: Tertiary referral center.Methods: All patients over 18 diagnosed with sudden sensorineural hearing loss between 2018 and 2021 who were treated with hyperbaric oxygen therapy were included. Demographic information, treatment regimens and duration, and audiometric and speech perception outcomes were recorded and analyzed.Results: 19 patients were included. The median age was 45 years. 53% were female and 21% had pre- existing rheumatologic disorders. The mean duration between hearing loss onset and physician visits was 9.6 days. All patients received an oral steroid course, while 95% also received a median of 3 intratympanic steroid injections. Patients began hyperbaric oxygen therapy an average of 34.2 days after the hearing loss onset for an average of 13 sessions. No significant relationships were found between patient comorbidities and outcomes. Of those who reported clinical improvement, 57% demonstrated complete recovery per Siegel's criteria. There was significant improvement after hyperbaric oxygen therapy for pure tone averages (50.3dB vs. 36.0dB, p<0.01) and word discrimination scores (73% vs 79%, p<0.05) for all patients regardless of reported clinical improvement.Conclusion: Hyperbaric oxygen therapy, as an adjunct to steroids, significantly improves recovery from sudden sensorineural hearing loss. The Charlson comorbidity index was not significantly associated with patient outcome, but patients with rheumatologic disorders were less likely to respond. Differentiating the natural history of the disease from hyperbaric oxygen therapy-associated improvements remains a challenge.","PeriodicalId":49396,"journal":{"name":"Undersea and Hyperbaric Medicine","volume":"51 4","pages":"393-402"},"PeriodicalIF":0.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

REPRINTED FROM THE 2023 HYPERBARIC INDICATIONS MANUAL 15^th Edition:Intracranial Abscess. 转载自2023高压氧适应症手册第15版：颅内脓肿。

IF 0.7 4区医学

Undersea and Hyperbaric Medicine Pub Date : 2024-04-01

Edward O Tomoye, Carrie L Park, Lind Folke, Richard E Moon

引用次数: 0